Attached files

file filename
EX-31.2 - CERTIFICATION PURSUANT TO SECURITIES EXCHANGE ACT RULE 13(A)-14(A) - Microbot Medical Inc.d311896dex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO SECURITIES EXCHANGE ACT RULE 13(A)-14(A) - Microbot Medical Inc.d311896dex311.htm
EX-23.1 - CONSENT OF GRANT THORNTON, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Microbot Medical Inc.d311896dex231.htm
EX-10.31 - STEMCELLS, INC. DIRECTOR'S FEE PLAN - Microbot Medical Inc.d311896dex1031.htm
EXCEL - IDEA: XBRL DOCUMENT - Microbot Medical Inc.Financial_Report.xls
10-K - FORM 10-K - Microbot Medical Inc.d311896d10k.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - Microbot Medical Inc.d311896dex322.htm

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the StemCells, Inc. (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin McGlynn, President and Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1). The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2). The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 14, 2012

/s/ Martin McGlynn

Martin McGlynn
President and Chief Executive Officer